Kahira Pharmaceuticals posts 53% YoY profit surge in Q1 FY2023/24: Egypt

Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharm aceutical products

Staff Writer, Arab Finance

November 16, 2023

PHOTO

Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 52.5% year-on-year (YoY) increase in net profits after tax for the first quarter of fiscal year (FY) 2023/2024, according to the company’s financial statement filed to the Egyptian Exchange (EGX) on November 14th.

CPCI’s net profits after tax stood at EGP 59.175 million for the three-month period ended September 30th, compared to EGP 38.796 million in the same period last FY.

Operating revenue grew by 33.1% YoY in Q1 of the current FY, hitting EGP 334.171 million, up from EGP 251.129 million.

Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.